# A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

> **NCT06972446** · PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 180 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Lutikizumab
- **DRUG:** Placebo
- **DRUG:** Ravagalimab

## Key facts

- **NCT ID:** NCT06972446
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2027-02
- **Final completion:** 2027-11
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06972446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06972446, "A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06972446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*